Cui Xiao-Yan, Wu Xiao, Lu Dan, Wang Dan
Hebei Institute for Drug and Medical Device Control, Shijiazhuang 050011, Hebei Province, China.
Department of Basic Medical, HE's University, Shenyang 110163, Liaoning Province, China.
World J Clin Cases. 2022 Jul 16;10(20):6900-6914. doi: 10.12998/wjcc.v10.i20.6900.
A comprehensive literature search shows that Sanqi and Huangjing (SQHJ) can improve diabetes treatment and , respectively. However, the combined effects of SQHJ on diabetes mellitus (DM) are still unclear.
To explore the potential mechanism of Panax notoginseng (Sanqi in Chinese) and Polygonati Rhizoma (Huangjing in Chinese) for the treatment of DM using network pharmacology.
The active components of SQHJ and targets were predicted and screened by network pharmacology through oral bioavailability and drug-likeness filtration using the Traditional Chinese Medicine Systems Pharmacology Analysis Platform database. The potential targets for the treatment of DM were identified according to the DisGeNET database. A comparative analysis was performed to investigate the overlapping genes between active component targets and DM treatment-related targets. We constructed networks of the active component-target and target pathways of SQHJ using Cytoscape software and then analyzed the gene functions. Using the STRING database to perform an interaction analysis among overlapping genes and a topological analysis, the interactions between potential targets were identified. Gene Ontology (GO) function analyses and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were conducted in DAVID.
We screened 18 active components from 157 SQHJ components, 187 potential targets for active components and 115 overlapping genes for active components and DM. The network pharmacology analysis revealed that quercetin, beta-sitosterol, baicalein, were the major active components. The mechanism underlying the SQHJ intervention effects in DM may involve nine core targets (TP53, AKT1, CASP3, TNF, interleukin-6, PTGS2, MMP9, JUN, and MAPK1). The screening and enrichment analysis revealed that the treatment of DM using SQHJ primarily involved 16 GO enriched terms and 13 related pathways.
SQHJ treatment for DM targets TP53, AKT1, CASP3, and TNF and participates in pathways in leishmaniasis and cancer.
全面的文献检索表明，三七和黄精可分别改善糖尿病治疗效果。然而，三七和黄精联合对糖尿病（DM）的影响仍不明确。
运用网络药理学探索三七和黄精治疗糖尿病的潜在机制。
通过网络药理学，使用中药系统药理学分析平台数据库，经口服生物利用度和类药性筛选，预测和筛选三七和黄精的活性成分及靶点。依据DisGeNET数据库确定糖尿病治疗的潜在靶点。进行对比分析以研究活性成分靶点与糖尿病治疗相关靶点之间的重叠基因。使用Cytoscape软件构建三七和黄精的活性成分 - 靶点网络以及靶点通路，随后分析基因功能。利用STRING数据库对重叠基因进行相互作用分析和拓扑分析，确定潜在靶点之间的相互作用。在DAVID中进行基因本体（GO）功能分析和京都基因与基因组百科全书富集分析。
我们从157种三七和黄精成分中筛选出18种活性成分，187个活性成分潜在靶点以及115个活性成分与糖尿病的重叠基因。网络药理学分析显示，槲皮素、β-谷甾醇、黄芩素等为主要活性成分。三七和黄精干预糖尿病的作用机制可能涉及9个核心靶点（TP53、AKT1、CASP3、TNF、白细胞介素 - 6、PTGS2、MMP9、JUN和MAPK1）。筛选和富集分析表明，三七和黄精治疗糖尿病主要涉及16个GO富集项和13条相关通路。
三七和黄精治疗糖尿病靶向TP53、AKT1、CASP3和TNF，并参与利什曼病和癌症相关通路。
